At Ajanta, we produce a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customised to each market we are present in. We clearly understand our customer's needs and use cutting edge technology to present innovative solutions.
We identify complex areas that need innovation and commit ourselves to find a solution, within a defined time frame. We extend this thought-process to the markets we choose to enter and the capabilities we want to build. The branded generics business is spread in India and more than 30 emerging countries across Africa, South East Asia, West Asia, and CIS.
India is at the heart of Ajanta's growth plans, with huge potential in the specialty segments. We have presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management where we have been able to provide consistently innovative products, many being 1st to the market, for patient convenience and compliance. This has enabled us to take leadership in many sub therapeutic segments we are present in. We continue to innovate and build a robust product pipeline for our future growth.
Emerging markets are the major contributors in our branded generic business where we are present across Asia and Africa. We chose each of the market where we are present in and designed a customised basket of products for each of these markets. We serve wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products.
Ajanta has been doing pioneering efforts in having ground presence through its own field force in the emerging markets and aggressively promoting brands to take leadership positions. We have also successfully carved an important position in the Philippines market in a very short period of time.
With the objective of building sustainable and scalable business model, we have been continuously filing products for registration in different countries of emerging markets, across therapeutic segments. This will ensure sustained growth for the company in years to come.